# Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC).

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/preliminary-results-from-cecilia-an-open-label-global-safety-study-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrés Redondo,Nicoletta Colombo,Lydia Dreosti,Mary McCormack,Angélica Nogueira Rodrigues,Margarita Donica,Leilani Morales,Antonio González-Martı́n |
| Citations | 5 |
| DOI | 10.1200/jco.2018.36.15_suppl.5528 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2890901936 |
| Type | conference-abstract |
| Year | 2018 |

## Paper authors

- [Angélica Nogueira Rodrigues](https://scholariq.org/researchers/angelica-nogueira-rodrigues/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Management of metastatic bone disease](https://scholariq.org/topics/management-of-metastatic-bone-disease/)

## Paper topics

- [Management of metastatic bone disease](https://scholariq.org/topics/management-of-metastatic-bone-disease/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Diagnosis and Treatment](https://scholariq.org/topics/cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.